ArticleVeterinary research communications2026
In vitro evaluation of the immunostimulatory effects of PAM2CS lipopeptide-based TLR2 agonists in chicken peripheral blood mononuclear cells.
Article in Veterinary research communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Although toll like receptor (TLR) ligands are effective vaccine adjuvants, current synthetic TLR2 agonists suffer from low solubility, high cost, and detrimental effect towards protein antigen. Present study aimed to evaluate the immunostimulatory potential of five in-house PAM2CS lipopeptide-based TLR2 agonists (P1, P2, P6, P7 and P8) using peripheral blood mononuclear cells (PBMCs) from chicken (n = 4). Each agonist (10 µg/mL) significantly upregulated the expression of interleukin (IL)-1 β and inducible nitric oxide synthase (iNOS) at 3 h post-treatment with highest expression of IL-1β mRNA was observed with P1. There was a significant up-regulation of interferon (IFN)-β and IFN-γ by treatment with P1 at 3 and 12 h intervals (p < 0.05). Further, IL-4 mRNA was significantly upregulated with P1 and P7 treatment at 12 and 24 h post-treatment respectively. Our results demonstrate that among all five agonists, P1 was the most effective in enhancing immune response genes expression including both type I and type II interferons, and in eliciting a balanced Th1 and Th2 responses.
Indexed as
Identifiers
42096121What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.